Merck and Moderna announce positive results for experimental mRNA skin cancer vaccine

American pharmaceutical giants Merck and Moderna have announced encouraging results from the final phase of clinical trials for their experimental messenger RNA (mRNA) treatment targeting skin cancer in patients with advanced melanoma. This development represents a significant step forward in cancer therapy.

The combined therapy, which pairs Moderna's personalized mRNA treatment, dubbed "intismeran autogene," with Merck's immunotherapy Keytruda, demonstrated a statistically significant improvement in relapse-free survival. This benefit was observed in patients who had previously undergone surgery for advanced melanoma. While the companies did not release specific figures, they stated that the combination therapy outperformed treatment with Keytruda alone.

This innovative treatment utilizes mRNA technology, instructing the body's cells to produce proteins that trigger an immune response. It is a "tailor-made" therapy, designed based on the unique mutations found in each patient's tumor. The goal is to train and activate the patient's immune system to effectively recognize and attack cancer cells.

Stéphane Bancel, CEO of Moderna, expressed enthusiasm for the breakthrough, stating, "For many years, the idea of creating an mRNA treatment specifically designed for a person's cancer was difficult to imagine. Today, we are helping to make that vision a reality." The Phase 3 trial, a crucial step before seeking marketing authorization, involved over 1,100 participants.

Moderna, widely recognized for its pioneering work in mRNA vaccines against COVID-19, is now applying this technology to cancer treatment. Merck and Moderna plan to present these findings at a medical conference and subsequently begin the process of seeking regulatory approval for the treatment. Melanoma, one of the deadliest forms of skin cancer, saw over 330,000 new cases diagnosed globally in 2022, a number that is reportedly increasing.